Reports
Patient care threatened by cancer drug shortages
Drug shortages are affecting most US oncologists, impacting on life-saving patient care, according to the findings of the largest study yet to quantify the impact of cancer drug shortages [1]. Of 250 board-certified US oncologists surveyed in late 2012 and early 2013, 83% reported facing a drug shortage in the past six months, and 92% of those said their patients’ treatment had been affected.
Biosimilar competition in Europe
A study of five European Union (EU) countries has revealed that Germany provides the most favourable environment for uptake of biosimilars.
International harmonization for biosimilars
What is the possibility of international harmonization for biosimilars? EMA Head of Biologicals Dr Peter Richardson and Amgen Director of Value, Access and Policy Mr Thomas Moore speak to BioCentury about this issue, as well as why the US is still lagging behind Europe in the biosimilars race.
Biosimilar monoclonal antibodies and pharmacovigilance in Europe
EMA Head of Biologicals Dr Peter Richardson and Amgen Director of Value, Access and Policy Mr Thomas Moore speak to BioCentury about biosimilar monoclonal antibodies and pharmacovigilance for biosimilars in Europe.
Possibility of substitution of biosimilars in Europe
To date, 14 biosimilars within the product classes of human growth hormone (1), granulocyte colony-stimulating factor (8) and erythropoietin (5) have been approved in Europe [1]. EMA Head of Biologicals Dr Peter Richardson and Amgen Director of Value, Access and Policy Mr Thomas Moore speak to BioCentury about substitution of biosimilars in Europe.
EMA’s Richardson talks about biosimilars in Europe
Biosimilars have been available in Europe for more than seven years. In the US, however, despite legislation being passed in 2010 to allow for a biosimilars pathway, a biosimilar has yet to be approved [1]. EMA Head of Biologicals Dr Peter Richardson speaks to BioCentury about a new report published by the European Commission (EC) and about biosimilars in Europe in general.
The best selling biotechnology drugs of 2008: the next biosimilars targets
Last updated: 20 September 2013
According to the report Market-Leading Biotechnology Drugs 2009: Blockbuster Dynamics in an Ailing Economy, sales of the top 10 biotech drugs exceeded US$41.5 billion (Euros 28.6 billion) in 2008.
Amgen, Hospira and Sandoz set to dominate US biosimilars market
A new report released by Thomson Reuters on 14 May 2013 identifies Amgen, Hospira and Sandoz as having the greatest potential to dominate the early stages of the biosimilars market in the US.
US places India on IP black list
The US has placed India on a special trade black list of countries that have raised concerns about intellectual property rights.
Use of biosimilars in Europe
Uptake of biosimilars in Europe is slowly increasing, according to a new report published by the European Commission’s (EC) Enterprise and Industry Directorate-General.
